ELN Diagnostics Gene Profiling Contact  · 

Contact Persons in Project 13: Gene Profiling

Created by: Hellenbrecht (ELIC) , generated 2006/03/14, last changed: 2008/06/11

Name	Initials	E-mail	Clinic	Country
Lead Participants
T. Haferlach	HAF		Münchner Leukämie Labor (MLL)	Germany
W. Hiddemann	HID		Ludwig-Maximilians-Universität	Germany
Participants
R. Apweiler	APW		European Molecular Biology Laboratory	UK
G. Barbany *	BARB		Uppsala Universitet	Sweden
G. Basso	BASS		Università degli Studi di Padova	Italy
G. Dighiero	DIG		Institut Pasteur	France
H. Döhner	DOE		Universität Ulm	Germany
M. Dugas	DUG		Department of Medical Informatics and Biomathematics, University of Münster	Germany
S. Ferrari	FER		University of Modena and Reggio Emilia	Italy
T. Fioretos	FIO			Sweden
R. Foa	FOA		Dipartimento di Biotecnologie Cellulari ed Ematologia, Università degli Studi di Roma "La Sapienza"	Italy
A. Gilkes *	GIL			UK
J.M. Hernandez-Rivas	HER		Fundación de Investigación del Cancer	Spain
W.-K. Hofmann	HOF		Klinikum Benjamin Franklin, Charite Berlin	Germany
J.H. Jansen	JAN		Stichting Katholieke Universiteit, Univ. Medical Center	Netherlands
J.V. Melo *	MELO		Imperial College London	UK
A. Neubauer	NEU		Philipps-Universität	Germany
B. Schlegelberger *	SCHL		Medizinische Hochschule Hannover	Germany
W. Seifarth	SEI		Ruprecht-Karls-Universität	Germany
H. Serve	SER		Universitätsklinikum Frankfurt	Germany
* = Female Researcher

Lead Participants:

Prof.Dr. T. Haferlach (Munich, Germany): Hematologist with longstanding experience in diagnosis and treatment of leukemia. The Medical Department III in Munich is running a central reference laboratory for the diagnosis of leukemias and includes all available techniques such as cytomorphology, cytochemistry, cytogenetics, FISH and 24-color FISH, CGH, multi-parameter immunophenotyping, PCR and real time PCR, and sequencing. Since 3/2001 also gene expression analyses are performed using the Affymetrix technology. The group can appply all techniques named above to several thousands of leukemia samples /year.

Prof.Dr. W. Hiddemann (Munich, Germany): Professor of Medicine, Hematology/Oncology. Long term prospective studies on AML, low grade lymphomas and neutropenic infections. Ethics in medicine.

Participants:

Dr. R. Apweiler (Cambridge, UK): Head of Sequence Database Group, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD.

Dr. G. Barbany (Uppsala, Sweden):

Prof.Dr. G. Basso (Padova, Italy): Associate Professor in Pediatrics, Head of the Laboratory for Oncohematology, Department of Pediatrics, University of Padova. He is in charge of the Biological Bank for acute leukemia’s of the AIEOP (Italian Association for Pediatric Hematology and Oncology) and is responsible for centralized diagnosis of all cases entering the Italian therapeutic protocols. His field of work includes all steps of laboratory work-up for diagnosis of leukemias, particularly flow cytometry for immunophenotyping, ploidy and functional studies. Started gene expression profiling analysis of pediatric leukemias.

Prof.Dr. G. Dighiero (Paris, France):

Prof.Dr. H. Döhner (Ulm, Germany):

Prof.Dr. M. Dugas (Münster, Germany):

Prof.Dr. S. Ferrari (Modena, Italy): Professor of Cell Biology, Head of the laboratory of cellular and molecular biology and of the DNA microarrays laboratory, Department of Biomedical Sciences, Section of Biochemistry, University of Modena and Reggio Emilia. Experience in molecular pathogenesis af AMLs and in the study of the genetic control of normal myelopoiesis. Responsible for gene expression profiling in normal and leukemic myelopoiesis using the Affymetrix platform.

T. Fioretos (, Sweden):

Prof.Dr. R. Foa (Rome, Italy):

A. Gilkes (, UK):

Dr. J.M. Hernandez-Rivas (Salamanca, Spain): Senior Physician, Head of the Laboratory for Molecular Cytogenetics, Department of Hematology, Hospital Universitario de Salamanca, Salamanca. Experience in molecular cytogenetics of leukemias, lymphomas and multiple myeloma. Mainly topics of interest: microarrays cyotgenetics, molecular biology, minimal residual disease. Responsible for a central reference laboratory that covers 30 hospitals for cytogenetic and molecular genetic diagnosis and for follow up studies. Responsible for gene expression profiling in leukemia using the Affymetrix platform.

Prof.Dr. W.-K. Hofmann (Berlin, Germany): University Hospital. Experience in gene expression profiling of normal hematopoietic stem cells and leukemic cells from patients with ALL and MDS using the Affymetrix -system. Specialized in analysis of small RNA-samples (nanogram-scale assay).

Dr. J.H. Jansen (Nijmegen, Netherlands): Head of Dept. of Molecular Hemato-Oncology and Molecular Diagnostics, Hematology UMCN Nijmegen. Coordinator of the molecular studies for the EORTC AML and MDS trials (AML-12, AML-17 and MDS-CRIANT studies). Head of reference laboratory. Chairman for the Dutch-Belgian-Swiss Network for molecular diagnostics in hemato-oncology in which all Dutch and various Belgian and Swiss centers participate.

Prof.Dr. J.V. Melo (London, UK): Professor of Molecular Hematology, Department of Hematology, Imperial College & Hammersmith Hospital, London, U.K. She heads a 15-member research laboratory where the main focus is the molecular biology of CML. She pioneered the investigations on the in vitro effects of the tyrosine kinase inhibitor imatinib mesylate which provided the essential basis for the design of the first clinical trials with this potent drug. For the past 6 years the group has concentrated in identifying the genes that are transcriptionally regulated by the BCR-ABL oncogene of CML, aiming at understanding the abnormal signals that underlie the leukemic process in hemopoietic progenitors. A second major area of investigation aims at understanding the mechanisms of resistance to imatinib so that more effective targeted therapeutic regimens can be designed for the treatment of CML.

Prof.Dr. A. Neubauer (Marburg, Germany): Significant experience in defining novel signalling pathways in myeloid diseases. Using gene array systems in order to discern specific pathways used by subgroups of AML in the near future possibly leading to the discovery of novel therapeutic alternatives in AML, and also in CML.

Prof.Dr. B. Schlegelberger (Hannover, Germany): Head of the Institute of Cell and Molecular Pathology, Hannover Medical School (MHH), Hannover, Germany. Main interest on the cytogenetic characterization of malignant lymphomas, on cloning of genes involved in lymphoma-genesis, on the development of FISH assays, on the combination of immunophenotyping and FISH (FICTION) and on the delineation of deleted regions, suspected to contain tumor suppressor genes. Recently, microarray and SELDI core facilities were established in the institute which was funded in 2001.

PD Dr. W. Seifarth (Heidelberg, Germany): III. Medizinische Klinik, Mannheim. Experience in gene expression profiling of normal and human tumor cells using self designed low density microarray systems based on Affymetrix-GMS technology (GMS-417 Arrayer & GMS-419 Array Scanner). Expertise in PCR-based analysis of low abundance transcripts.

Prof.Dr. H. Serve (Frankfurt, Germany):